Premium
Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2‐non‐amplified metastatic breast cancer
Author(s) -
Lim Elgene,
Beith Jane,
Boyle Frances,
Boer Richard,
Hui Rina,
McCarthy Nicole,
Redfern Andrew,
Wade Theresa,
Woodward Natasha
Publication year - 2018
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.13065
Subject(s) - metastatic breast cancer , breast cancer , cyclin dependent kinase 4 , palbociclib , medicine , context (archaeology) , oncology , hormone receptor , cancer , human epidermal growth factor receptor 2 , endocrine system , cancer research , hormone , cell cycle , biology , cyclin dependent kinase 2 , paleontology
Cyclin‐dependent kinase (CDK4/6) inhibitors in combination with endocrine therapy are currently the optimal first line treatment for hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) non‐amplified metastatic breast cancer (MBC). However, not all patients benefit from this treatment and all patients will inevitably progress. Identifying therapeutic strategies in this setting is therefore of immediate clinical importance. We present an overview of the mechanisms of resistance to CDK4/6 inhibitors and review potential biomarkers that may guide therapy selection. We also discuss the use of CDK4/6 inhibitors in the context of non‐HR‐positive/HER2‐non‐amplified breast cancer and in combination with therapies other than endocrine therapy.